What is Imcyse?
Imcyse is a pioneering biopharmaceutical entity focused on the development of Imotopes, which are synthetic peptides designed to induce specific immune responses. By recalibrating the patient's immune system, the company seeks to provide long-term solutions for debilitating diseases such as Type 1 Diabetes, Multiple Sclerosis, and Rheumatoid Arthritis. The company operates at the intersection of immunology and biotechnology, maintaining a robust pipeline that bridges the gap between pre-clinical research and human clinical trials. Its market position is defined by its collaborative model, engaging with academic institutions and global pharmaceutical partners to validate its technology and scale its therapeutic impact.
How much funding has Imcyse raised?
Imcyse has raised a total of $25.6M across 1 funding round:
Series B
$25.6M
Series B (2021): $25.6M with participation from Epimedic, Pfizer, Life Sciences Partners, Noshaq, K.U.Leuven, SRIW, Biogenosis, and SFPI Group
Key Investors in Imcyse
Pfizer
Pfizer is a global biopharmaceutical leader that researches, develops, and manufactures medicines and vaccines across multiple therapeutic areas, including inflammation and immunology.
Life Sciences Partners
A prominent European venture capital firm specializing in life sciences, focusing on high-growth companies that develop innovative medical technologies and therapeutics.
SRIW
Wallonie Entreprendre serves as a key economic and financial tool for the Wallonia region, providing strategic financing and expertise to foster growth in healthcare and deep tech sectors.
What's next for Imcyse?
With the infusion of this major strategic investment, Imcyse is poised to transition its lead candidates through critical clinical milestones. The company's roadmap focuses on expanding its clinical trial footprint and refining the manufacturing processes for its synthetic peptide platform. As the firm moves toward potential commercialization, the focus will likely shift toward establishing strategic partnerships that can facilitate global distribution and regulatory approval. The current funding context suggests a transition from early-stage development to a more mature, scaling phase, where the primary objective is to demonstrate clinical efficacy and safety in larger patient cohorts, thereby solidifying its role as a leader in the next generation of autoimmune disease therapeutics.
See full Imcyse company page
